Logo
homeHome
toggle_offCompany ProfilegroupsBoards & Staffsworkspace_premiumMemberships & PartnersschoolAcademy of Journalismperson_addCareerslinkBlog(EN)emailContact Us
list_altOur JournalslightbulbInstruction for AuthorsbookmarkBrieflands PolicieshandshakePublish My Researchplay_circleJournal Management Systemcredit_cardArticle Processing Chargeszoom_inOpen Peer ReviewimagePublishing Services
menu_bookPublish My Book
  1. Brieflands
  2. journals
  3. IJ Pharmaceutical Research
  4. Articles

  5. In Vivo and Bioinformatics Evaluation of Nine Traditional Chinese Medicine Compounds Targeting Acetylcholinesterase and Butyrylcholinesterase Enzymes in Alzheimer’s Disease
  6. Crossref

IJ Pharmaceutical Research

homeHome
play_arrowCurrent Issueformat_list_bulletedAll Issuesformat_indent_increaseIn Presscheck_boxAccepted Manuscripts
searchSearchqr_codeInstructions
bookmarkJournal InformationgroupsEditors & BoardsshareIndexing and Listing Sourceswaterfall_chartJournal Metricszoom_inOpen Peer Review (OPR)balancePublication Ethics and Malpractice Statementassignment_indReviewer and AE Registration FormemailSupportphoneContact Us
menuAPC
Authors GuideSubmit Manuscript

Crossref


1. Design, Hemi-synthesis, DFT calculations, and In Silico Profiling of Novel α-Isocostic Acid Derivatives: Potent Anticancer Candidates Targeting Topoisomerase IIα with Dual Anti-tyrosinase and Anti-AChE activity

- Mariem Aouidene

- Noura Bouabidi

- Dorsaf Jebri

- Mansour Znati

- Maroua Jalouli

- Mohamed Othman

- Hichem Ben Jannet

HomeSearchInstructionsAPC

Archives

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.